Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

By D. Grady, David Herrington, Vera Bittner, Roger S. Blumenthal, Michael Davidson, M. Hlatky, Judith Hsia, S. Hulley, Alan Herd, Steven Khan and 4 more. Journal of the American Medical Association (JAMA), 2002

1,917 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics

View Paper: https://www.semanticscholar.org/paper/3db870999a3a0b7ec9466118419f040ec7a2c20d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Ringleb
2. Álvaro Cervara
3. G. Ford
4. M. Walker
5. M. Bousser
6. M. Brainin
7. Á. Chamorro
8. V. Caso

Citations in the corpus

• Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. (2003, neutral): “Hormone replacement with estrogen/ progestin is no longer recommended for primary [84] or secondary [85] CHD prevention (A-I).”
• Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. (2008, methodology): “According to the HERS II trial, hormone replacement in healthy women is associated with an increased risk of ischaemic stroke [255].”